For the quarter ending 2026-03-31, PTGX has $697,459K in assets. $41,986K in debts. $193,712K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Contract asset | - | - | - | 23,363 |
| Cash and cash equivalents | 193,712 | 128,390 | 113,713 | 168,543 |
| Marketable securities | 354,074 | 438,974 | 462,404 | 401,922 |
| Receivable from collaboration partner | 53,663 | 121 | 583 | - |
| Prepaid expenses and other current assets | 12,006 | 10,089 | 9,724 | 8,698 |
| Total current assets | 613,455 | 577,574 | 586,424 | 602,526 |
| Marketable securities - noncurrent | 72,548 | 78,638 | 102,703 | 102,493 |
| Property and equipment, net | 3,778 | 3,860 | 4,100 | 4,108 |
| Restricted cash - noncurrent | 288 | 287 | 287 | 290 |
| Operating lease right-of-use asset | 7,390 | 7,829 | 8,174 | 8,589 |
| Total assets | 697,459 | 668,188 | 701,688 | 718,006 |
| Accounts payable | 8,437 | 5,339 | 5,646 | 3,249 |
| Accrued expenses and other payables | 17,491 | 28,269 | 22,868 | 15,397 |
| Deferred revenue | 6,282 | 9,550 | 14,200 | 14,688 |
| Operating lease liability | 2,339 | 2,283 | 2,228 | 2,173 |
| Total current liabilities | 34,549 | 45,441 | 44,942 | 35,507 |
| Deferred revenue - noncurrent | - | - | 2,788 | 5,375 |
| Operating lease liability - noncurrent | 7,437 | 8,040 | 8,521 | 9,106 |
| Total liabilities | 41,986 | 53,481 | 56,251 | 49,988 |
| Common stock, 0.00001 par value, 180,000,000 shares authorized 64,227,057 and 62,577,897 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 1 | 1 | 1 | 1 |
| Additional paid-in capital | 1,122,629 | 1,084,736 | 1,071,198 | 1,054,980 |
| Accumulated other comprehensive (loss) income | -269 | 641 | 525 | -15 |
| Accumulated deficit | -466,888 | -470,671 | -426,287 | -386,948 |
| Total stockholders' equity | 655,473 | 614,707 | 645,437 | 668,018 |
| Total liabilities and stockholders' equity | 697,459 | 668,188 | 701,688 | 718,006 |
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)